---
title: "Amgen Inc. (AMGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AMGN.US.md"
symbol: "AMGN.US"
name: "Amgen Inc."
industry: "Biotechnology"
datetime: "2026-04-14T08:26:13.867Z"
locales:
  - [en](https://longbridge.com/en/quote/AMGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AMGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AMGN.US.md)
---

# Amgen Inc. (AMGN.US)

## Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.amgen.com](https://www.amgen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-14T04:30:16.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.95% |  |
| Net Profit YoY | 88.53% |  |
| P/B Ratio | 21.81 |  |
| Dividend Ratio | 2.76% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 188792782659.46 |  |
| Revenue | 36751000000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 106.10% | A |
| Profit Margin | 20.98% | A |
| Gross Margin | 70.78% | A |
| Revenue YoY | 9.95% | B |
| Net Profit YoY | 88.53% | A |
| Total Assets YoY | -1.36% | D |
| Net Assets YoY | 47.32% | A |
| Cash Flow Margin | 129.14% | B |
| OCF YoY | 9.95% | B |
| Turnover | 0.40 | C |
| Gearing Ratio | 90.44% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Amgen Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.95%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "88.53%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "21.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.76%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "188792782659.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "36751000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "106.10%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "20.98%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "70.78%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.95%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "88.53%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.36%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "47.32%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "129.14%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "9.95%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.40",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "90.44%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 24.48 | 44/393 | 26.52 | 25.30 | 24.04 |
| PB | 21.81 | 422/393 | 24.87 | 21.66 | 19.20 |
| PS (TTM) | 5.14 | 106/393 | 5.13 | 4.68 | 4.44 |
| Dividend Yield | 2.76% | 5/393 | 3.26% | 3.11% | 2.76% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-13T04:00:00.000Z

Total Analysts: **34**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 26% |
| Overweight | 4 | 12% |
| Hold | 18 | 53% |
| Underweight | 1 | 3% |
| Sell | 2 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 349.82 |
| Highest Target | 432.00 |
| Lowest Target | 200.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AMGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AMGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AMGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AMGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**